Tvardi Therapeutics, a clinical-stage biopharmaceutical company developing oral small molecule therapies targeting STAT3, announced it will present at Chardan’s 10th Annual Healthcare Conference in New York City on October 20, 2026. The company focuses on treatments for inflammatory and proliferative diseases and is advancing clinical trials for its drug candidates TTI-109 and TTI-101. This presentation offers investors insight into Tvardi’s progress and future plans in drug development for diseases like gastrointestinal disorders and liver cancer.
Tvardi Therapeutics' participation in a healthcare conference is the subject. For readers following the health sector, here is Pluang's market snapshot as of Oct 14, 2026 19:01 WIB: Out of 150 priced US health stocks, 105 rose and 40 fell. ClearPoint Neuro Inc (CLPT) rose 3.36% to USD 10.14 with 100% buy orders and a typical hold time of 10 days. Guardant Health Inc (GH) fell 2.40% to USD 158.20 with 100% buy orders and a hold time of 3 days. DENTSPLY SIRONA Inc (XRAY) rose 2.18% to USD 8.69 with a typical hold time of 72 days.
Genesis Global won the Best AI Solution for Software Development award at the 2026 AI in Capital Markets Awards for its product Genesis Create. This software combines AI with reusable components and financial expertise to help firms develop productio...
nuVizz has been recognized as an Accelerator in the 2026 Nucleus Research Transportation Management Value Matrix for its specialized last-mile delivery technology. The platform excels in coordinating complex delivery networks involving private fleets...
ASML Holding posted a strong Q3 2026 earnings per share of $14.65, beating estimates of $12.17, driven by a 55% year-over-year sales growth and a 57.5% gross margin. Although revenue was slightly below expectations at $13.05 billion, the company bene...
Charles Schwab is set to report its Q3 2026 earnings with an estimated EPS of $1.66 and revenue around $7.18-$7.19 billion, reflecting significant growth driven by an 18.2% increase in trading revenue, net interest income, and asset management fees. ...
Transmission System Operators (TSOs) are increasingly investing in software like Energy Management Systems and grid planning tools to modernize aging infrastructure, enhance cybersecurity, and expand grid capacity. Cybersecurity remains their top con...
